Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product ...

Cash burn is likely to moderate going forward, as investments in Schrödinger's internal pipeline have now stabilized. Read ...

Despite a decline in total revenue, Schrodinger Inc (SDGR) showcases robust software performance and strategic collaborations ...

Novartis AG (NYSE:NVS) Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, expectations were $1.8. Operator: Good morning and good ...

The transaction is expected to close in the first half of 2025. Also Read: Novartis Q4 Earnings: Revenue And EPS Beat, CEO Dismisses Entresto Patent Expiration Worries The transaction aligns with ...

Last week, Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges ...

Last week, Swiss pharma giant Novartis NVS reported better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates. Core earnings (excluding one-time charges) of ...

Novartis’ Q4 results aligned with Deutsche Bank’s revenue expectations but surpassed projections on margins and the FY25 outlook. The firm expects sales to grow in the mid-to-high single ...

Novartis’ Q4 results aligned with Deutsche Bank’s revenue expectations but surpassed projections on margins and the FY25 outlook. The firm expects sales to grow in the mid-to-high single digits at ...